ATE321134T1 - Menschlicher fc-gamma-rezeptor iii - Google Patents

Menschlicher fc-gamma-rezeptor iii

Info

Publication number
ATE321134T1
ATE321134T1 AT97106398T AT97106398T ATE321134T1 AT E321134 T1 ATE321134 T1 AT E321134T1 AT 97106398 T AT97106398 T AT 97106398T AT 97106398 T AT97106398 T AT 97106398T AT E321134 T1 ATE321134 T1 AT E321134T1
Authority
AT
Austria
Prior art keywords
human
gamma receptor
receptor iii
variants
image
Prior art date
Application number
AT97106398T
Other languages
English (en)
Inventor
Gary A Peltz
Kevin W Moore
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Application granted granted Critical
Publication of ATE321134T1 publication Critical patent/ATE321134T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
AT97106398T 1988-05-27 1989-05-24 Menschlicher fc-gamma-rezeptor iii ATE321134T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19951388A 1988-05-27 1988-05-27
US30003989A 1989-01-19 1989-01-19

Publications (1)

Publication Number Publication Date
ATE321134T1 true ATE321134T1 (de) 2006-04-15

Family

ID=26894851

Family Applications (2)

Application Number Title Priority Date Filing Date
AT97106398T ATE321134T1 (de) 1988-05-27 1989-05-24 Menschlicher fc-gamma-rezeptor iii
AT89305241T ATE197053T1 (de) 1988-05-27 1989-05-24 Humaner rezeptor fc(gamma)riii

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT89305241T ATE197053T1 (de) 1988-05-27 1989-05-24 Humaner rezeptor fc(gamma)riii

Country Status (10)

Country Link
US (2) US5976831A (de)
EP (3) EP0449828A1 (de)
JP (1) JP2657221B2 (de)
KR (1) KR0149012B1 (de)
AT (2) ATE321134T1 (de)
AU (1) AU3740089A (de)
DE (3) DE68929546T4 (de)
ES (2) ES2262163T3 (de)
GR (1) GR3034698T3 (de)
WO (1) WO1989011490A1 (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE321134T1 (de) 1988-05-27 2006-04-15 Applied Research Systems Menschlicher fc-gamma-rezeptor iii
US5767077A (en) * 1988-05-27 1998-06-16 Applied Research Systems Ars Holding N.V. Human Fc-γ receptor III
US7038031B1 (en) * 1989-07-28 2006-05-02 Sloan-Kettering Institute For Cancer Research DNA encoding FcγR receptor protein on NK cells
FR2655269B1 (fr) * 1989-12-01 1994-02-11 Curie Universite Pierre Marie Proteines empechant l'interaction entre un fragment fc d'une immunoglobuline et son recepteur et utilisation en therapeutique, notamment dans le traitement des affections liees aux virus hiv.
FR2702481B1 (fr) * 1993-03-09 1995-04-28 Roussel Uclaf Nouveaux récepteurs Fc-gamma III humains solubles, leur procédé de préparation, les compositions pharmaceutiques les contenant, leur application comme médicaments et leur application diagnostique.
US5641863A (en) * 1993-09-30 1997-06-24 University Of Pennsylvania Chimeric IgG Fc receptors
EP0679716A4 (de) * 1993-11-12 1999-06-09 Kenichi Matsubara Genetische Signaturen.
US6444789B1 (en) 1995-05-03 2002-09-03 Applied Research Systems Ars Holding N.V. CD16-II variants
FR2739560B1 (fr) * 1995-10-09 1997-11-21 Roussel Uclaf Utilisation d'un polypeptide ayant l'activite du cd16 humain soluble dans le traitement de l'infection par le virus vih
US7468139B2 (en) 1997-07-15 2008-12-23 Silverbrook Research Pty Ltd Method of depositing heater material over a photoresist scaffold
US7556356B1 (en) 1997-07-15 2009-07-07 Silverbrook Research Pty Ltd Inkjet printhead integrated circuit with ink spread prevention
US6935724B2 (en) 1997-07-15 2005-08-30 Silverbrook Research Pty Ltd Ink jet nozzle having actuator with anchor positioned between nozzle chamber and actuator connection point
US7195339B2 (en) 1997-07-15 2007-03-27 Silverbrook Research Pty Ltd Ink jet nozzle assembly with a thermal bend actuator
US7465030B2 (en) 1997-07-15 2008-12-16 Silverbrook Research Pty Ltd Nozzle arrangement with a magnetic field generator
US6682174B2 (en) 1998-03-25 2004-01-27 Silverbrook Research Pty Ltd Ink jet nozzle arrangement configuration
US6188415B1 (en) 1997-07-15 2001-02-13 Silverbrook Research Pty Ltd Ink jet printer having a thermal actuator comprising an external coil spring
US6712453B2 (en) 1997-07-15 2004-03-30 Silverbrook Research Pty Ltd. Ink jet nozzle rim
US6648453B2 (en) 1997-07-15 2003-11-18 Silverbrook Research Pty Ltd Ink jet printhead chip with predetermined micro-electromechanical systems height
US7287836B2 (en) * 1997-07-15 2007-10-30 Sil;Verbrook Research Pty Ltd Ink jet printhead with circular cross section chamber
EP1006183A1 (de) * 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Rekombinante, lösliche Fc-Rezeptoren
CA2463746C (en) * 2001-10-19 2014-09-02 Centre Hospitalier Regional Et Universitaire De Tours Methods and compositions to evaluate antibody treatment response
CA2487932A1 (en) 2002-05-30 2003-12-11 Macrogenics, Inc. Cd16a binding proteins and use for the treatment of immune disorders
US8946387B2 (en) 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8044180B2 (en) 2002-08-14 2011-10-25 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8968730B2 (en) 2002-08-14 2015-03-03 Macrogenics Inc. FcγRIIB specific antibodies and methods of use thereof
US8530627B2 (en) 2002-08-14 2013-09-10 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
PT1534335E (pt) 2002-08-14 2012-02-28 Macrogenics Inc Anticorpos específicos de fcγriib e processos para a sua utilização
US8193318B2 (en) 2002-08-14 2012-06-05 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8187593B2 (en) 2002-08-14 2012-05-29 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US7355008B2 (en) 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
AU2004204817C1 (en) 2003-01-13 2011-01-20 Macrogenics, Inc. Soluble FcyR fusion proteins and methods of use thereof
CA2565874C (en) 2004-05-10 2017-10-03 Macrogenics, Inc. Humanized fc.gamma.riib-specific antibodies and methods of use thereof
US20070231813A1 (en) * 2004-06-01 2007-10-04 Centre Hospitalier Regional Et Universitaire De Tours Fcgr3a Gebotype and Methods for Evaluating Treatment Response to Non-Depleting Antibodies
WO2005123947A1 (en) * 2004-06-15 2005-12-29 Universite Francois Rabelais Methods of assessing susceptibility to drug-induced thrombocytopenia
ES2678094T3 (es) * 2004-07-10 2018-08-08 Fox Chase Cancer Center Líneas de células asesinas naturales genéticamente modificadas
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
SG164379A1 (en) 2005-07-21 2010-09-29 Genmab As Potency assays for antibody drug substance binding to an fc receptor
DK2573114T3 (en) 2005-08-10 2016-07-04 Macrogenics Inc The identification and production of antibodies with variant Fc regions, and methods of using same
CA2660592C (en) 2006-05-26 2016-07-12 Macrogenics, Inc. Humanized fc.gamma.riib-specific antibodies and methods of use thereof
EP2032159B1 (de) 2006-06-26 2015-01-07 MacroGenics, Inc. Kombination aus fcgammariib-antikörpern und cd20-spezifischen antikörpern sowie verwendungsverfahren dafür
EP2029173B1 (de) 2006-06-26 2016-07-20 MacroGenics, Inc. Fc-riib-spezifische antikörper und verfahren zu ihrer anwendung
US8652466B2 (en) 2006-12-08 2014-02-18 Macrogenics, Inc. Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
SG189730A1 (en) 2008-04-02 2013-05-31 Macrogenics Inc Her2/neu-specific antibodies and methods of using same
CN106349390B (zh) 2008-04-02 2019-12-10 宏观基因有限公司 Bcr-复合体-特异性抗体和其使用方法
MX2012004029A (es) 2009-10-07 2012-05-08 Macrogenics Inc Polipeptidos que contienen la region fc que exhiben funcion efectora mejorada debido a alteraciones del grado de fucosilacion, y metodos para su uso.
EP3498730B1 (de) 2009-12-21 2026-01-28 Regeneron Pharmaceuticals, Inc. Mäuse mit humanisiertem fc-gamma-r
US8883496B2 (en) 2009-12-21 2014-11-11 Regeneron Phamaceuticals, Inc. Humanized FcgR mice
DK2542256T3 (da) 2010-03-04 2019-08-26 Macrogenics Inc Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
EP2492689B8 (de) * 2011-02-22 2013-12-25 Bernhard-Nocht-Institut für Tropenmedizin Nachweis von Antikörpern mit einem verbesserten Immunkomplex- (IC) ELISA
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
RS60398B1 (sr) 2014-04-08 2020-07-31 Regeneron Pharma Ne-humane životinje sa humanizovanim fc-gama receptorima
EP3162895B1 (de) * 2014-06-27 2020-11-25 Tosoh Corporation Verbessertes fc-bindendes protein, verfahren zur herstellung dieses proteins und antikörperadsorbens mit diesem protein sowie verfahren zur antikörpertrennung unter verwendung des besagten adsorbens
CN109069633A (zh) 2016-04-15 2018-12-21 宏观基因有限公司 新颖的b7-h3-结合分子、其抗体药物缀合物及其使用方法
IL277355B2 (en) 2018-03-26 2025-01-01 Regeneron Pharma Humanized rodents for testing therapeutic agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US199153A (en) * 1878-01-15 Improvement in sulky-plows
WO1987007277A1 (en) * 1986-05-29 1987-12-03 The University Of Melbourne Fc receptor for immunoglobulin
FR2611913B1 (fr) * 1987-02-24 1994-04-15 Khayat David Procede de dosage des recepteurs fc gamma solubles seriques, coffret de dosage correspondant et applications
WO1989008114A1 (en) * 1988-02-25 1989-09-08 The General Hospital Corporation Rapid immunoselection cloning method
ATE321134T1 (de) * 1988-05-27 2006-04-15 Applied Research Systems Menschlicher fc-gamma-rezeptor iii

Also Published As

Publication number Publication date
EP0449828A1 (de) 1991-10-09
ATE197053T1 (de) 2000-11-15
KR0149012B1 (ko) 1998-08-17
EP0791653B9 (de) 2006-08-30
EP0343950B1 (de) 2000-10-18
GR3034698T3 (en) 2001-01-31
ES2150898T3 (es) 2000-12-16
US6294347B1 (en) 2001-09-25
DE68929256D1 (de) 2000-11-23
KR900701843A (ko) 1990-12-04
JP2657221B2 (ja) 1997-09-24
EP0343950A3 (de) 1991-07-10
DE68929546T4 (de) 2007-03-08
DE68929256T2 (de) 2001-05-17
AU3740089A (en) 1989-12-12
DE68929546D1 (de) 2006-05-11
EP0343950A2 (de) 1989-11-29
US5976831A (en) 1999-11-02
EP0791653B1 (de) 2006-03-22
EP0791653A1 (de) 1997-08-27
JPH03501484A (ja) 1991-04-04
WO1989011490A1 (en) 1989-11-30
DE68929546T2 (de) 2006-09-21
HK1001403A1 (en) 1998-06-19
ES2262163T3 (es) 2006-11-16

Similar Documents

Publication Publication Date Title
DE68929546D1 (de) Menschlicher Fc-gamma-Rezeptor III
DK1266965T3 (da) Rekombinante antistoffer til human terapi
DE3789973D1 (de) Zahnimplantat zur Befestigung von Zahnersatz-Suprakonstruktionen.
DE3750342D1 (de) Menschliches gamma-interferon-spezifisches Rezeptorprotein, Antikörper gegen dieses Protein, Verfahren zur Herstellung dieses Proteins und dieses Antikörpers und dieses Protein und diesen Antikörper enthaltende Zusammensetzungen.
DK1260521T3 (da) Immunoglobulinvarianter af specifikke Fc-epsilonreceptorer
EP0261224A4 (de) Synthetische htlv-iii-peptid-zusammensetzungen und ihre verwendung.
ATE162079T1 (de) Verwendung von antikörper enthaltenden präparationen zur immunsuppression
DK228190A (da) Rajgraespollenallergen
DE3876400D1 (de) Aminosaeure-imid-derivate, ihre verwendung und diese enthaltende medizinische zusammensetzungen.
DK175843B1 (da) Polypeptider af overfladeaktive alvelolarproteiner (ASP), farmaceutisk sammensætning indeholdende polypeptidet, DNA-ekspressionssystem der koder for polypeptidet, samt fremgangsmåde til fremstilling af polypeptider med ASP-aktivitet
DE3852625D1 (de) Vektoren und Verbindungen zur Expression von Zymogen-Formen von menschlichem Protein C.
NO893794D0 (no) Fremgangsmaate for fremstilling av forbedret hydrolysert protein.
FI873606A7 (fi) Ihmisen glykoalbumiinin määrittämiseen käyttökelpoisia vasta-aineita.
AU666482B2 (en) Human herpesvirus type 6 protein p100, the corresponding DNA sequences, their preparation and use
NO881502D0 (no) Rekombinante htlv-111 proteiner og anvendelse av disse.
ATE189262T1 (de) Interferon-alpha/beta bindendes protein, seine herstellung und seine enthaltende pharmazeutische zusammensetzungen
DK319384A (da) 1-0-alkyl-3-amino-propan-1,2-diol-2-0-phospholipider, fremgangsmaade til deres fremstilling samt farmaceutiske praeparater indeholdende disse
IL86710A0 (en) Polypeptide receptor for interleukin-2,antibodies against this polypeptide and pharmaceutical compositions containing the same
NO170936C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive, substituerte vinylcefalosporiner
IT1262898B (it) Antigeni ricombinanti proteici ad aumentata immunogenicita' contenenti il peptide rappresentato dalla sequenza vqgeesndk
NO893796D0 (no) Fremgangsmaate for fremstilling av forbedret hydrolysert protein.
BR6802052U (pt) Mascara cirurgica descartavel retangular com cadarcos costurados pelo sistema hrow(hight resfst one way)
NO893795L (no) Fremgangsmaate for fremstilling av forbedret hydrolysert protein.
NO875477D0 (no) Rekombinant alveolaert overflateaktivt protein.
EP0511516A3 (en) Schizosaccharomyces specific polypeptide

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0791653

Country of ref document: EP

EELA Cancelled due to lapse of time